Because miR-21 overexpression and KRAS mutation have been extensively reported to be a part of a PDAC signature with a strong clinical correlation for PDAC progression and survival [9, 10, 13], we hypothesized that dual targeting of these two key players could improve the anti-cancer effects. This evidence concerns the gene KRAS and cancer.